
Yayınlanma: 16 Mart 2021 18:49
Güncellenme: 4 Aralık 2025 21:49
Veeva (NYSE: VEEV) offers cloud-based software products and services to more than 900 customers in the global life sciences market.
These products and services support pharmaceutical and biotech companies in the use of multiple functions, including clinical research, data management, regulatory compliance, quality control, and customer relationship management.
Veeva dominates the CRM market within the scope of life sciences. This puts it in a great position in the foreseeable future. Veeva has been steadily growing more than 25 percent over the past three years, and there's no reason to assume that this will stop.
Assuming that pharmaceuticals and biotechnology will continue to expand, investments in the development and marketing of products will surely continue to increase.
Data analytics and artificial intelligence will help these companies minimize costs and improve patient outcomes. Of course, those who provide this technology infrastructure must also be successful.
Veeva's dominance in this market will be very difficult to erode. These are great signs for long-term thinking shareholders.
Source: https://www.fool.com/
You may also be interested in:




